In recent years, the widespread use of genomic sequencing panels in cancer treatment has promised more personalized and effective therapies. However, a recent study conducted by the Breast Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) reveals that the current clinical practice of using these panels benefits only 5% of patients, primarily due to inconsistent adherence to recommended clinical criteria.
Genomic sequencing panels are tests that examine the DNA of a patient's tumor to identify genetic variants for which targeted drugs exist. When tumors possess these variants, treatments can be tailored accordingly, forming the basis of precision oncology. However, the study led by Miguel Ángel Quintela analyzed 139 cases from two Madrid hospitals and found that the survival rates were significantly higher in patients whose panels were utilized in accordance with clinical guidelines.
The study underscores the importance of following established clinical criteria when implementing genomic sequencing panels. The researchers stress that such panels should be recommended for patients with metastatic lung, colon, or melanoma cancer who are candidates for first-line treatment. In these cases, multiple genetic variants with corresponding targeted drugs can be identified more efficiently through a comprehensive panel rather than individual variant analysis.
Furthermore, the panels prove valuable for patients participating in clinical trials, individuals with rare tumors lacking clear treatment standards, and cases where tumors exhibit unexpected responses to drugs. By uncovering new associations between genetic variants and drug responses, these panels enhance treatment efficacy and patient survival when applied according to recommended clinical criteria.
Conversely, rapidly progressing tumors, cancers with established treatment options not requiring complete genomic profiling, and patients with limited life expectancies are not ideal candidates for genomic sequencing panels. The study emphasizes the importance of real-world evidence in assessing the effectiveness and risks/benefits of tests and treatments beyond controlled clinical trials.
Financial considerations also come into play, as both the panels and subsequent treatments are costly and not typically covered by public health systems or private insurance. It is crucial to determine the utility of these tests to avoid unnecessary expenses and potential delays in initiating appropriate treatment.
The researchers emphasize the importance of providing health professionals with clear recommendations to guide their clinical decisions. They acknowledge that each case is unique, and exceptions may arise where panels are employed despite not aligning with recommended guidelines. Nonetheless, the study's authors expect that the findings will have practical implications for clinicians, highlighting the need for categorized clinical judgment and prioritizing panel testing for advanced cancers requiring multiple genetic markers, rare cancers, or patients being screened for molecular clinical trials.
Genomic sequencing panels are tests that examine the DNA of a patient's tumor to identify genetic variants for which targeted drugs exist. When tumors possess these variants, treatments can be tailored accordingly, forming the basis of precision oncology. However, the study led by Miguel Ángel Quintela analyzed 139 cases from two Madrid hospitals and found that the survival rates were significantly higher in patients whose panels were utilized in accordance with clinical guidelines.
The study underscores the importance of following established clinical criteria when implementing genomic sequencing panels. The researchers stress that such panels should be recommended for patients with metastatic lung, colon, or melanoma cancer who are candidates for first-line treatment. In these cases, multiple genetic variants with corresponding targeted drugs can be identified more efficiently through a comprehensive panel rather than individual variant analysis.
Furthermore, the panels prove valuable for patients participating in clinical trials, individuals with rare tumors lacking clear treatment standards, and cases where tumors exhibit unexpected responses to drugs. By uncovering new associations between genetic variants and drug responses, these panels enhance treatment efficacy and patient survival when applied according to recommended clinical criteria.
Conversely, rapidly progressing tumors, cancers with established treatment options not requiring complete genomic profiling, and patients with limited life expectancies are not ideal candidates for genomic sequencing panels. The study emphasizes the importance of real-world evidence in assessing the effectiveness and risks/benefits of tests and treatments beyond controlled clinical trials.
Financial considerations also come into play, as both the panels and subsequent treatments are costly and not typically covered by public health systems or private insurance. It is crucial to determine the utility of these tests to avoid unnecessary expenses and potential delays in initiating appropriate treatment.
The researchers emphasize the importance of providing health professionals with clear recommendations to guide their clinical decisions. They acknowledge that each case is unique, and exceptions may arise where panels are employed despite not aligning with recommended guidelines. Nonetheless, the study's authors expect that the findings will have practical implications for clinicians, highlighting the need for categorized clinical judgment and prioritizing panel testing for advanced cancers requiring multiple genetic markers, rare cancers, or patients being screened for molecular clinical trials.